Doxorubicin clinical trials
Also written Adriamycin, Rubex, Adriablastin and NSC-123127.
Its developmentBy 16 companies, company by company34 company-led studies, furthest phase 4: when each phase was reached, its deals, target and what is ahead.Includes 210 studies of Liposomal doxorubicin.
Related medicines add 1 study
Counted the way a researcher would: Doxorubicin with its salts, dosage forms, brands and biosimilars. Looking for a trial to join? Including related medicines shows more you could take part in.
This browser remembers your choice.
How each study uses Doxorubicin is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Doxorubicin studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 7 Aug 1974 · DOXORUBICIN HYDROCHLORIDE · NDA 050467 (FDA, Drugs@FDA)
- European Union
- 20 Jun 1996 · Caelyx pegylated liposomal · EMEA/H/C/000089 (EMA; as liposomal doxorubicin)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- NSC-123127
- 5
Studies by the year they started
767 studies that test it; most in 2008 (48); 1 more planned to start later
| Year | Studies |
|---|---|
| 1990 | 1 |
| 1992 | 4 |
| 1993 | 2 |
| 1994 | 7 |
| 1995 | 7 |
| 1996 | 9 |
| 1997 | 16 |
| 1998 | 20 |
| 1999 | 20 |
| 2000 | 24 |
| 2001 | 23 |
| 2002 | 25 |
| 2003 | 33 |
| 2004 | 45 |
| 2005 | 35 |
| 2006 | 44 |
| 2007 | 39 |
| 2008 | 48 |
| 2009 | 38 |
| 2010 | 25 |
| 2011 | 17 |
| 2012 | 25 |
| 2013 | 25 |
| 2014 | 15 |
| 2015 | 24 |
| 2016 | 29 |
| 2017 | 21 |
| 2018 | 18 |
| 2019 | 31 |
| 2020 | 12 |
| 2021 | 14 |
| 2022 | 15 |
| 2023 | 18 |
| 2024 | 8 |
| 2025 | 16 |
| 2026 | 14 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 102 · Other 677
National Cancer Institute (NCI) (45) · M.D. Anderson Cancer Center (40) · Children's Oncology Group (28) · Memorial Sloan Kettering Cancer Center (20) · University of Washington (14) · St. Jude Children's Research Hospital (13) · European Organisation for Research and Treatment of Cancer - EORTC (11) · Alliance for Clinical Trials in Oncology (11)
Often tested with
Tested in the same studies.
Cyclophosphamide (271) · Vincristine (155) · Prednisone (105) · Etoposide (98) · Paclitaxel (86) · Cisplatin (80) · Dexamethasone (67) · Ifosfamide (67)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 42 phase 3 studies under way
Doxorubicin is the comparator. A study of two new drugs counts under both.
- 4Mocertatug rezetecan · GlaxoSmithKline, Hansoh BioMedical R&D Company · next primary completion Mar 2027
- 3Rinatabart sesutecan · Genmab · next primary completion Sep 2027
- 3Sacituzumab tirumotecan · Merck Sharp & Dohme LLC · next primary completion Jul 2027
- 2Cediranib · National Cancer Institute (NCI)
- 2Olaparib · National Cancer Institute (NCI)
- 2Lenalidomide · The Lymphoma Academic Research Organisation, Ruijin Hospital · next primary completion Nov 2028
- 2Axicabtagene ciloleucel · Kite, A Gilead Company · next primary completion Oct 2030
- 2Raludotatug deruxtecan · Merck Sharp & Dohme LLC, Daiichi Sankyo · next primary completion Feb 2028
Reaching primary completion within a year · 36, 8 in phase 3
Studies that test Doxorubicin, phase 3 first.
- Nov 2026High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)Phase 3 · Gustave Roussy, Cancer Campus, Grand Paris
- Dec 2026Benefit of Intensified Peri-operative Chemotherapy Within High-risk CINSARC Patients With Resectable Soft-tissue SarcomasPhase 3 · Institut Bergonié
- Dec 2026Paediatric Hepatic International Tumour TrialPhase 3 · University of Birmingham
- Dec 2026Capizzi Escalating Methotrexate Versus High Dose Methotrexate in Children With Newly Diagnosed T-cell Lymphoblastic Lymphoma (T-LBL)Phase 3 · Children's Cancer Group, China
- Jun 2027A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)Phase 3 · Genmab
- Jun 2027Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and AdolescentsPhase 3 · University Hospital Muenster
- Sep 2027Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract CancerPhase 2/3 · National Cancer Institute (NCI)
- Oct 2027PPI Versus Histamine Antagnists as Adjuvant to ChemotherapyPhase 3 · Sherief Abd-Elsalam
- Dec 2026Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic CarcinomaPhase 2 · Memorial Sloan Kettering Cancer Center
- Dec 2026Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified ChemotherapyPhase 2 · St. Jude Children's Research Hospital
Studies
Open first, then newest update. How each study uses Doxorubicin is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 779
- Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract CancerRecruitingPhase 2/3National Cancer Institute (NCI)NCT04628767Written as Doxorubicin HydrochlorideHow we know
- Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell LymphomaRecruitingPhase 2National Cancer Institute (NCI)NCT04002947Written as CHOPHow we know
- Testing the Addition of a New Anti-Cancer Drug, Glofitamab to Usual Chemotherapy for Burkitt and Double Hit LymphomaRecruitingPhase 2/3National Cancer Institute (NCI)NCT07724457Written as DoxorubicinHow we know
- Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced SarcomaRecruitingPhase 1National Cancer Institute (NCI)NCT05711615Written as Pegylated Liposomal Doxorubicin HydrochlorideHow we know
- Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal HistologiesRecruitingPhase 1National Cancer Institute (NCI)NCT04847063Written as DoxorubicinHow we know
- Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast CancerRecruitingPhase 3National Cancer Institute (NCI)NCT06058377Written as DoxorubicinHow we know
- SATURN-STS: Phase II Study of Neoadjuvant Atezolizumab With Doxorubicin, Concurrent Atezolizumab With Pre-operative Radiation Therapy and Adjuvant Atezolizumab in Patients With High-risk Surgically Resectable Extremity and Truncal Soft Tissue SarcomaRecruitingPhase 2M.D. Anderson Cancer CenterNCT07049848Written as Doxorubicin HydrochlorideHow we know
- The CARDIOPROTECT TrialNot yet recruitingPhase 2Beth Israel Deaconess Medical CenterNCT07654426Written as DoxorubicinHow we know
- Efficacy and Safety of Polatuzumab Vedotin, Rituximab Combined With Reduced-dose Cyclophosphamide, Doxorubicin and Prednisone Regimen in the Treatment of Elderly Patients With Diffuse Large B-cell Lymphoma: A Multicenter, Single-arm, Prospective StudyRecruitingPhase 4The First Hospital of Jilin UniversityNCT07908888Written as DoxorubicinHow we know
- Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)RecruitingPhase 2National Cancer Institute (NCI)NCT01419561Written as Liposomal DoxorubicinHow we know
- Sequential Neoadjuvant Chemotherapy in Soft Tissue SarcomaRecruitingPhase 2Oslo University HospitalNCT04776525Written as DoxorubicinHow we know
- Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin LymphomaRecruitingPhase 2University of WashingtonNCT07097363Written as DoxorubicinHow we know
- ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin LymphomaRecruitingPhase 2Michael Spinner, MDNCT07021989Written as Liposomal DoxorubicinHow we know
- A Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell LymphomaRecruitingPhase 2University of RochesterNCT03758989Written as DoxorubicinHow we know
- Phase II Decentralized Pragmatic Trial of Adjuvant Doxorubicin - Trabectedin Chemotherapy in uLMSRecruitingPhase 2M.D. Anderson Cancer CenterNCT07076186Written as Doxorubicin HydrochlorideHow we know
- Interest of Post-operative Chemotherapy in Patients With Localised Uterine Leiomyosarcoma Suspected of Having a High Risk of Recurrence Based on a Biological Test Performed on the TumourRecruitingPhase 2UNICANCERNCT06524583Written as DoxorubicinHow we know
- Utidelone Capsules Combined With Doxorubicin for Advanced Soft Tissue SarcomaNot yet recruitingPhase 2Beijing Biostar Pharmaceuticals Co., Ltd.NCT07842276Written as UTD2 + tislelizumab + doxorubicinHow we know
- Metastatic Ewing's Trial Testing Schedule Enhancement to Improve OutcomesRecruitingPhase 1H. Lee Moffitt Cancer Center and Research InstituteNCT07194044Written as DoxorubicinHow we know
- Pembrolizumab and Radiation Therapy With or Without Neoadjuvant Doxorubicin and Ifosfamide for the Treatment of High-Risk Resectable Undifferentiated Pleomorphic Sarcoma or Liposarcoma of the Extremity or Trunk WallNot yet recruitingPhase 3Ohio State University Comprehensive Cancer CenterNCT07823491Written as DoxorubicinHow we know
- Personalized Reduction of Chemotherapy Intensity Through ctDNA Evaluation for the Treatment of Patients With Advanced Hodgkin LymphomaRecruitingPhase 2University of WashingtonNCT06745076Written as DoxorubicinHow we know
See all 779 studies that test Doxorubicin →
Given beside what is tested · 707 — Doxorubicin is usual care or a partner of the new treatment
- Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)RecruitingPhase 1National Cancer Institute (NCI)NCT04301076Written as Doxorubicin HydrochlorideHow we know
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged LeukemiaRecruitingPhase 2National Cancer Institute (NCI)NCT06317662Written as DoxorubicinHow we know
- Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated SarcomasRecruitingPhase 3National Cancer Institute (NCI)NCT06422806Written as DoxorubicinHow we know
- Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ TrialRecruitingPhase 2National Cancer Institute (NCI)NCT03907475Written as Pegylated Liposomal Doxorubicin HydrochlorideHow we know
- BrECADD Therapy in Stage 2 B-IV Hodgkin LymphomaRecruitingPhase 2University of MiamiNCT07002216Written as DoxorubicinHow we know
- Epcoritamab in Combination With Dose Adjusted EPOCH-R for High-risk Burkitt Lymphoma (BL), The BEDROCK StudyRecruitingPhase 2AIDS Malignancy ConsortiumNCT07662928Written as DoxorubicinHow we know
- Doxorubicin Plus Dacarbazine Versus Doxorubicin Alone as First-Line Therapy for Metastatic or Recurrent Uterine LeiomyosarcomaRecruitingPhase 2Blokhin's Russian Cancer Research CenterNCT07942168Written as DoxorubicinHow we know
- A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)RecruitingPhase 2Merck Sharp & Dohme LLCNCT06890884Written as DoxorubicinHow we know
- A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)RecruitingPhase 3Merck Sharp & Dohme LLCNCT06717347Written as DoxorubicinHow we know
- A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)RecruitingPhase 2/3Merck Sharp & Dohme LLCNCT07634471Written as Doxorubicin HydrochlorideHow we know
- A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and NivolumabRecruitingPhase 3National Cancer Institute (NCI)NCT05675410Written as Doxorubicin HydrochlorideHow we know
- Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin LymphomaRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT03618550Written as liposomal doxorubicinHow we know
- A Study of Azenosertib (ZN-c3) in Patients With Ovarian CancerRecruitingPhase 1K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, IncNCT04516447Written as Pegylated liposomal doxorubicinHow we know
- Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell LymphomasRecruitingPhase 1City of Hope Medical CenterNCT07278856Written as DoxorubicinHow we know
- Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell LymphomaNot yet recruitingPhase 1National Cancer Institute (NCI)NCT07444710Written as DoxorubicinHow we know
- Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian CancerRecruitingPhase 2Regeneron PharmaceuticalsNCT06787612Written as PLDHow we know
- Personalized Cancer Vaccine (PCV) Strategy in Triple Negative Breast Cancer PatientsNot yet recruitingPhase 1Washington University School of MedicineNCT07300475Written as DoxorubicinHow we know
- A Study With NKT3964 for Adults With Advanced/Metastatic Solid TumorsRecruitingPhase 1NiKang Therapeutics, Inc.NCT06586957Written as DoxorubicinHow we know
- AMC 120, Glofitamab Plus Chemoimmunotherapy in Newly Diagnosed HIV-Associated Large B-Cell Lymphoma (The "Glofit-RCHOP Study")RecruitingPhase 1National Cancer Institute (NCI)NCT07649304Written as Doxorubicin HydrochlorideHow we know
- US/PA/E Imaging for Early Identification of Tumor Response in Patients With Stage II-III Triple Negative Breast Cancer Receiving Neoadjuvant Immunotherapy and ChemotherapyNot yet recruitingPhase 2Emory UniversityNCT07862751Written as DoxorubicinHow we know
Showing 20 of 707.
As the comparator · 129 — what is tested is compared with Doxorubicin
- Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance TherapyRecruitingPhase 2National Cancer Institute (NCI)NCT07504588Written as Pegylated Liposomal Doxorubicin HydrochlorideHow we know
- A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)RecruitingPhase 3Merck Sharp & Dohme LLCNCT06966700Written as DoxorubicinHow we know
- A Clinical Trial of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab in Participants With Ovarian Cancer Who Have Progressed During Treatment With PARP-inhibitors Treatment on First Line Maintenance (MK-5909-008/ENGOT-ov107/GOG-3142 / REJOICE-Ovarian05)RecruitingPhase 3Merck Sharp & Dohme LLCNCT07743164Written as Pegylated liposomal doxorubicin (PLD)How we know
- A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003).RecruitingPhase 1/2Merck Sharp & Dohme LLCNCT06843447Written as Pegylated liposomal doxorubicinHow we know
- Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)RecruitingPhase 2Merck Sharp & Dohme LLCNCT06797635Written as Doxorubicin hydrochlorideHow we know
- A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular LymphomaRecruitingPhase 3Regeneron PharmaceuticalsNCT06091254Written as DoxorubicinHow we know
- A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine CancerRecruitingPhase 3BioNTech SENCT06340568Written as DoxorubicinHow we know
- A Study of QLS5132 in Platinum-Resistant Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal CancerNot yet recruitingPhase 3Qilu Pharmaceutical Co., Ltd.NCT07926048Written as Liposomal DoxorubicinHow we know
- A Trial to Evaluate the Efficacy of Pirtobrutinib and Epcoritamab Compared With R-(Mini)-CHOP for Treatment of Patients With DLBCL-type Richter TransformationRecruitingPhase 2German CLL Study GroupNCT07917780Written as DoxorubicinHow we know
- Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian CancerRecruitingPhase 3GenmabNCT07564141Written as PLDHow we know
- A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian CancerRecruitingPhase 3Eli Lilly and CompanyNCT07213804Written as Pegylated liposomal doxorubicin (PLD)How we know
- A Study to Investigate Mocertatug Rezetecan Compared With Chemotherapy in Participants With Endometrial Cancer After Platinum-based Chemotherapy and Immunotherapy (BEHOLD-Endometrial01)RecruitingPhase 3GlaxoSmithKlineNCT07286331Written as DoxorubicinHow we know
- An Extension Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer in ChinaRecruitingPhase 3GenmabNCT07604766Written as Pegylated liposomal doxorubicin (PLD)How we know
- A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)RecruitingPhase 3Merck Sharp & Dohme LLCNCT07060807Written as Pegylated liposomal doxorubicinHow we know
- A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian CancerRecruitingPhase 3Verastem, Inc.NCT06072781Written as Pegylated liposomal doxorubicinHow we know
- A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube CancerRecruitingPhase 2/3Daiichi SankyoNCT06161025Written as PLDHow we know
- A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)RecruitingPhase 3GlaxoSmithKlineNCT07286266Written as Pegylated liposomal doxorubicin (PLD)How we know
- A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)RecruitingPhase 3Merck Sharp & Dohme LLCNCT06312176Written as Liposomal doxorubicinHow we know
- A Study to Investigate Mocertatug Rezetecan With Bevacizumab Compared With Platinum Doublet With Bevacizumab in Participants With Platinum-sensitive Ovarian Cancer (BEHOLD-Ovarian02)RecruitingPhase 3GlaxoSmithKlineNCT07684612Written as Pegylated liposomal doxorubicin (PLD)How we know
- Trastuzumab Rezetecan and Carboplatin ± Bevacizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-sensitive Recurrent Ovarian CancerNot yet recruitingPhase 2Sun Yat-sen UniversityNCT07776171Written as Carboplatin + pegylated liposomal doxorubicinHow we know
Showing 20 of 129.
What changed recently
From the registry's own updates since Oct 20, 2026.
Started recruiting1
Results posted1
Stopped1
Codes
What other systems call Doxorubicin · ClinicalTrials.gg INT007399
- MeSH (NLM) D004317DoxorubicinConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 80168379AGDOXORUBICINConfirmed FDA, NLM, Wikidata
- RxNorm 3639Confirmed FDA, Wikidata
- Wikidata Q18936doxorubicinConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C456DoxorubicinOne source FDA
- DrugBank DB00997One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D004317 | Doxorubicin | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 80168379AG | DOXORUBICIN | Confirmed FDA, NLM, Wikidata |
| RxNorm | 3639 | — | Confirmed FDA, Wikidata |
| Wikidata | Q18936 | doxorubicin | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C456 | Doxorubicin | One source FDA |
| DrugBank | DB00997 | — | One source Wikidata |
Also registered as doxorubicin citrate (UNII AJQ2ZNG2WL) and doxorubicin hydrochloride (UNII 82F2G7BL4E · RxNorm 142433).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.